Finny logo
Finny logo
Dibs:
Dibs:
0

Aurinia Pharmaceuticals (AUPH) earnings: expect 77% revenue growth

1:35 pm ET, 08 May 2019

Aurinia Pharmaceuticals (AUPH) is announcing earnings on May 09. We combed through analyst estimates to understand what the company revenue and earnings are predicted to look like.

What should you expect from the upcoming earnings?

Revenue for the next quarter is expected to be $0M, which implies a 77% growth rate year-over-year.

Earnings per share are expected to come in at $-0.16. If this materializes, EPS will grow 11% year-over-year.

How did the stock do last month?

Over the last month, Aurinia Pharmaceuticals (AUPH) returned -7.32%.

What do analysts say about the stock?

Aurinia Pharmaceuticals (AUPH) average analyst price target is 207.66% above its current price ($6.27).

For the latest price and information on Aurinia Pharmaceuticals, please visit Finstead and ask for "AUPH", "AUPH analysis" or "AUPH news".

Aurinia Pharmaceuticals (AUPH): a long-term play?

7:37 am ET, 09 Aug 2018

Aurinia Pharmaceuticals Inc (AUPH) shares are trading at 5.27, down -2%. What's driving AUPH stock price? What's AUPH stock price forecast?

Recently the company initiated a Phase 2 clinical trial evaluating a drug called voclosporin ophthalmic solution (VOS) for the treatment of dry eyes. This drug will be evaluated against Allergan's RESTASIS over a four-week treatment period in 90 patients with mild-to-moderate dry eye syndrome.  The trial should be completed by the end of the year.

Aurinia has also expanded its focus area for VOS, which is being investigated in focal segmental glomerulosclerosis (FSGS).  The pipeline expansion significantly reduces AUPH's risk profile and makes it an attractive proposition to investors.  

Let's look at the sentiment towards the AUPH stock.  Our technical analysis shows that:

  • The stock short-term sentiment (next 30 days) is negative;
  • The mid-term sentiment (3-6 months) is trending negative;
  • The long-term sentiment (9-12 months) is trending positive. 

Over the last month, Aurinia Pharmaceuticals Inc (AUPH) returned -5.16%.

Aurinia Pharmaceuticals Inc (AUPH) average analyst price target ($14.90) is 179.55% above its current price ($5.33).

For the latest price and information on Aurinia Pharmaceuticals Inc, please visit Finstead and search for "AUPH price" or "AUPH news".

Aurinia Pharmaceuticals is a clinical-stage biopharmaceutical company, which primary business is the development of a therapeutic drug to treat autoimmune diseases, in particular, lupus nephritis (LN). It is focused on the development of its lead compound voclosporin to treat patients afflicted with LN.  Voclosporin is an oral drug, administered twice daily. 

Aurinia Pharmaceuticals Inc (AUPH) Stock Guide

Updated at: 11:43 am ET, 17 Sep 2020

Before we start: if you're looking for AUPH stock price, you can quickly find it out by visiting Finny and typing "AUPH quote". If you're looking for a quick scoop on AUPH stock (chart, price target, market cap, news and buy or sell analysis), go to Finny and look for "AUPH". You'll get all this info in one place. Or you can just type "AUPH news" to get the latest stock news.

Looking to buy or sell Aurinia Pharmaceuticals Inc (AUPH)? Interested in getting the full scoop on AUPH, including earnings and dividends, stock forecast, buy or sell analysis and key stats? If so, you came to the right place.

In this AUPH stock guide, we'll address key questions about AUPH, above and beyond what you can find on Yahoo Finance, Zacks, MarketWatch or Morningstar.

Here is what you'll be able to find in this guide:

Earnings and Dividends: earnings, earnings date, dividend rate and dividend yield;
Analyst Predictions: stock forecast and analyst ratings;
Analysis: Finny Score and buy or sell analysis;
Key Stats: revenue, market cap, revenue growth, profit margin, P/E ratio, P/B ratio, industry, sector, and number of employees.

And here is the list of questions we'll answer:
1. What are AUPH earnings?
2. What is AUPH stock forecast (i.e., prediction)?
3. AUPH buy or sell? What is AUPH Finny Score?
4. What are the reasons to buy AUPH? Why should I buy AUPH stock?
5. What are the reasons to sell AUPH? Why should I sell AUPH stock?
6. What are AUPH key stats: revenue, market cap, revenue growth, profit margin, P/E ratio, P/B ratio industry, sector, and number of employees?

So let's start. Scroll down to the question that interests you the most.

Earnings and Dividends

1. What are AUPH earnings?

AUPH trailing 12-month earnings per share (EPS) is -$1.36.

Analyst Predictions

2. What is AUPH stock forecast (i.e., prediction)?

Based on AUPH analyst price targets, AUPH stock forecast is $11.50 (for a year from now). That means the average analyst price target for AUPH stock is $11.50. The prediction is based on 5 analyst estimates.

The low price target for AUPH is $9.00, while the high price target is $14.00.

AUPH analyst rating is Buy.

Analysis

3. AUPH buy or sell? What is AUPH Finny Score?

#{finnyScore:57}Our quantitative analysis shows 4 reasons to buy and 3 reasons to sell AUPH, resulting in Finny Score of 57.

4. What are the reasons to buy AUPH? Why should I buy AUPH stock?

Here are the reasons to buy AUPH stock:

5. What are the reasons to sell AUPH? Why should I sell AUPH stock?

Let's look at the reasons to sell AUPH stock (i.e., the bear case):

Key Stats

6. What are AUPH key stats : revenue, market cap, revenue growth, profit margin, P/E ratio, P/B ratio industry, sector, and number of employees?

Let's look at the key statistics for AUPH:

Metrics AUPH
Price $15.89
Average Price Target / Upside $11.50 / -27.63%
Average Analyst Rating Buy
Forward Dividend Yield 0.00%
Industry Biotechnology
Sector Healthcare
Number of Employees 33
Market Cap $1.97B
Forward P/E Ratio -28.33
Price/Book Ratio 6191.34
Revenue (TTM) $318K
YoY Quarterly Revenue Growth 0.00%
Profit Margin 0.00%

If you liked this analysis, check out Stock Guides for other stocks.

Follow Us